Condition: AL Amyloidosis · Amyloidosis · Sponsor: University of Texas Southwestern Medical Center
The goal of this study is to test the safety of drug, Belantamab Mafodotin, and see what effects (good and bad) it has on people who take it and have amyloidosis, and to determine the most effective dose of the drug. The study will have 2 phases (parts). The first phase of the study will test different doses of Belantamab Mafodotin. The second phase will test Belantamab Mafodotin at the dose level found to be safe and effective in phase 1
This description comes directly from the study's public registry record.
Donglan Xia · 214-648-7097 · Donglan.Xia@UTSouthwestern.edu
Always discuss trial participation with your own doctor first.
| Vanderbilt Ingram Cancer Center | Nashville, Tennessee, United States | Not Yet Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Huntsman Cancer Institute, University of Utah | Salt Lake City, Utah, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05145816